Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Co-Development Deal Brings Bristol A Novel Interferon, ZymoGenetics Much-Needed Cash

This article was originally published in The Pink Sheet Daily

Executive Summary

Formerly legal adversaries, the two companies will co-develop PEG-interferon lambda, currently in Phase Ib for hepatitis C.
Advertisement

Related Content

ZymoGenetics Snags $70M Payout From BMS For Phase II Start Of New Interferon
Ahead of ASCO, Exelixis Inks Lucrative Deal With Sanofi For Its PI3 Kinase Inhibitors
Refocusing ZymoGenetics Cuts Staff, Seeds Pipeline Of Private Startup Firm
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2009
Big Pharma’s March Into Biotech Could Make Big Biologics A Big ’09 Theme
Big Pharma's March Into Biotech Could Make Big Biologics A Big '09 Theme
Deals Of The Week: Wyeth/Santaris, Novartis/HHS, Cephalon/Ception ...
Novartis/HGS’ Albuferon ACHIEVEs Non-inferiority To Pegasys For Hepatitis C
Bristol’s Take On Restructuring: Cut $1.5 Bil. In Costs, Try BioPharma Model
Bristol’s Take On Restructuring: Cut $1.5 Bil. In Costs, Try BioPharma Model

Topics

Advertisement
UsernamePublicRestriction

Register

PS068466

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel